Skip to content
Top Globe News – Lifestyle
Author:
Aplagon
Aplagon Announces EUR 5 Million Financing to Broaden Phase 2 Trials of its APAC Therapy in Thrombo-Inflammatory Diseases
June 16, 2026
Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases
June 1, 2026
Aplagon Announces First Patient Dosed in Phase 2a Clinical Trial of APAC in Patients with Peripheral Arterial Occlusive Disease / Chronic Limb Threatening Ischemia
March 12, 2026